Related references
Note: Only part of the references are listed.Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma
Olivia M. Dong et al.
VALUE IN HEALTH (2022)
Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews
Chantelle Garritty et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness
Peter Murphy et al.
MEDICAL DECISION MAKING (2021)
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine
Denis Horgan et al.
CANCERS (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials
Liyun Jiang et al.
CONTEMPORARY CLINICAL TRIALS (2021)
PCN198 Statistical Methods for Pantumor Analysis: Models to Account for Tumor-Level Heterogeneity
A. Swaminathan et al.
VALUE IN HEALTH (2021)
Drug Development in Tissue-Agnostic Indications
Pauline du Rusquec et al.
CANCERS (2021)
Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies
Jennifer G. Gaultney et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2021)
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
C. B. Westphalen et al.
NPJ PRECISION ONCOLOGY (2021)
An overview of precision oncology basket and umbrella trials for clinicians
Jay J. H. Park et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2020)
Site-agnostic biomarker-guided oncology drug development
Jan Trost Jorgensen
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2020)
Tumour-agnostic therapies
Ann-Marie Looney et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
Sophie Cooper et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Histology independent cancer drugs: the drug makers' responsibility
Daniel A. Ollendorf
BMJ-BRITISH MEDICAL JOURNAL (2020)
PCN262 Understanding the Challenges in the Evaluation of Tumour-Agnostic Therapies: Barriers Posed By the Current Trial Designs and Future Trends
N. Delimpaltadakis et al.
VALUE IN HEALTH (2020)
RE1 Financing and Reimbursement for Personalised Medicine - Are WE There YET?
R. Koleva-Kolarova et al.
VALUE IN HEALTH (2020)
PCN233 Communicating VALUE to Payers for Tumor-Agnostic Therapies
M. Hunt et al.
VALUE IN HEALTH (2020)
PPM2 Decision Modelling Approaches for Histology-Independent Cancer Technologies
R. Hodgson et al.
VALUE IN HEALTH (2020)
PPM12 DATA Collection and Heterogeneity: Implications for Histology-Independent Decision Making
P. Murphy et al.
VALUE IN HEALTH (2020)
HTA1 Adaptive Pathways for Tumour Agnostic Medicines in Various Developed Markets
M. Rodes Sanchez et al.
VALUE IN HEALTH (2020)
PCN241 Complex Innovative Design Trials: Too Complex for Market Access?
P. Hartikainen et al.
VALUE IN HEALTH (2020)
Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation
Sabine Vogler et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2020)
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials
Adam C. Palmer et al.
CELL SYSTEMS (2020)
CHALLENGES AND AN APPROACH TO PERFORMING COST-EFFECTIVENESS ANALYSES BASED ON SINGLE ARM BASKET TRIALS FOR PAN-TUMOR INDICATIONS
P. Orfanos et al.
VALUE IN HEALTH (2019)
PCN343 INVESTIGATING EUROPEAN HTA AND PRICING FOR HISTOLOGY-AGNOSTIC TREATMENTS
C. Boehmer et al.
VALUE IN HEALTH (2019)
TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?
B. Khogeer et al.
VALUE IN HEALTH (2018)
Precision medicine becomes reality-tumor type-agnostic therapy
Li Yan et al.
CANCER COMMUNICATIONS (2018)
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
Matthew D. Galsky et al.
INVESTIGATIONAL NEW DRUGS (2010)
Simultaneous and Sequential Qualitative Mixed Method Designs
Janice M. Morse
QUALITATIVE INQUIRY (2010)
Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups
Allison Tong et al.
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2007)